more

Zealand Pharma A/S (ZEAL)

(Delayed Data from NSDQ)

$20.45 USD

+0.29 (1.45%)

Updated May 3, 2019 03:59 PM ET

After-Market: $20.26 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study

by Zacks Equity Research Published on September 13,2022

Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).

Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?

by Zacks Equity Research Published on July 21,2022

Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study

by Zacks Equity Research Published on January 21,2022

Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

biotechs

Zealand Pharma AS (ZEAL) Moves 8.3% Higher: Will This Strength Last?

by Zacks Equity Research Published on May 19,2021

Zealand Pharma AS (ZEAL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

ZEALPositive Net Change

Biotech Stock Roundup: REGN Cocktail Data Positive, INCY's Jakafi Disappoints & More

by Zacks Equity Research Published on March 24,2021

The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Regeneron (REGN) and Incyte (INCY).

Zealand (ZEAL) Surges: Stock Moves 9.1% Higher

by Zacks Equity Research Published on July 01,2020

Zealand (ZEAL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

medical

Zealand Announces Dosing Initiation in Type 2 Diabetes Study

by Zacks Equity Research Published on June 25,2020

Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.